STOCK TITAN

Beyond Air Inc - XAIR STOCK NEWS

Welcome to our dedicated news page for Beyond Air (Ticker: XAIR), a resource for investors and traders seeking the latest updates and insights on Beyond Air.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Beyond Air's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Beyond Air's position in the market.

Rhea-AI Summary
Beyond Air, Inc. (NASDAQ: XAIR) reports solid revenue growth, increased demand for LungFit PH, FDA acceptance for label expansion, and positive clinical trial progress. The company reiterated revenue guidance for FY 2025 and announced key milestones for its various programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.67%
Tags
earnings
-
Rhea-AI Summary
Beyond Air, Inc. (NASDAQ: XAIR) will report financial results for its third fiscal quarter on February 12th, 2024. The company's management team will host a conference call and webcast at 4:30 pm Eastern Time the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.02%
Tags
earnings
-
Rhea-AI Summary
Beyond Cancer, Ltd. (NASDAQ: XAIR) announced that the Phase 1 study evaluating ultra-high concentration nitric oxide (UNO) in advanced, relapsed, or refractory unresectable, primary, or metastatic cutaneous and subcutaneous solid tumors has cleared the first cohort of 25,000 ppm single dose UNO with no reported dose limiting toxicities. The study continues to recruit eligible patients in the next protocol-defined cohort of 50,000 ppm in multiple centers in Israel.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.88%
Tags
clinical trial
Rhea-AI Summary
Beyond Air, Inc. (NASDAQ: XAIR) announced that Steve Lisi, Chairman and CEO, will participate in a fireside discussion and one-on-one meetings at the Piper Sandler Healthcare Conference. The discussion will focus on the company's initiatives in harnessing nitric oxide to improve the lives of patients with respiratory illnesses, neurological disorders, and solid tumors. The event will take place on November 30th, 2023, in New York City.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.96%
Tags
conferences
-
Rhea-AI Summary
Beyond Air, Inc. (XAIR) provides fiscal year 2025 revenue guidance of $12 - $16 million while making significant strides in the US hospital market with LungFit PH, licensed LungFit PH in certain Asian markets, and submitting a PMA supplement to the FDA for cardiac surgery. The company also presented preclinical and human data for treatment of solid tumors with UNO and began the United States VCAP study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.03%
Tags
earnings
-
Rhea-AI Summary
Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc., announced positive clinical biomarker data from a Phase 1 study of their ultra-high concentration nitric oxide (UNO) therapy for solid tumors. The data demonstrate evidence of immune system activation and a promising safety profile. The treatment showed an immunostimulatory effect, with increases in cytotoxic T-cells, T-central memory cells, and M1 macrophages. T-regulatory cells and myeloid derived suppressor cells decreased. The therapy was well tolerated with primarily Grade 1 toxicities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.91%
Tags
clinical trial
Rhea-AI Summary
Beyond Air, Inc. to report financial results for its second fiscal quarter on November 13th
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.07%
Tags
earnings
-
Rhea-AI Summary
Beyond Air, Inc. to present at Truist Securities BioPharma Symposium
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.17%
Tags
conferences
-
Rhea-AI Summary
Beyond Cancer, Ltd. has published pre-clinical data showing that its UNO therapy reduces immunosuppression and creates a favorable tumor microenvironment. Initial clinical data will be released on November 3rd at the SITC Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.48%
Tags
clinical trial
Rhea-AI Summary
Beyond Cancer, Ltd. to present two proffered posters at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023. Intratumoral administration of Ultra High-Concentration Nitric Oxide (UNO) and Anti PD-1 treatment leads to high tumor regression rates and prolonged survival in tumor-bearing mice. Ultra-high concentration nitric oxide (UNO) enhances anti-CTLA-4 treatment activity and induces a durable anti-tumor response.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.9%
Tags
conferences
Beyond Air Inc

Nasdaq:XAIR

XAIR Rankings

XAIR Stock Data

69.56M
28.48M
20.96%
26.3%
8.84%
Other Industrial Machinery Manufacturing
Manufacturing
Link
US
Garden City

About XAIR

Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System, LungFit™, that uses NO generated from ambient air to deliver precise amounts of NO to the lungs of ventilated and non-ventilated patients for the potential treatment of a variety of pulmonary diseases. LungFit™ can generate up to 400 ppm of NO for delivery either continuously or for a fixed amount of time, and has the ability to either titrate dose on demand or maintain a constant dose. The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for respiratory tract infections that are not effectively addressed with current standards of care. Beyond Air is currently advancing its innovative LungFit™ in clinical trials for the treatment of severe lung infections such as SARS-CoV-2 and nontuberculous mycobacteria (NTM). Additionally, Beyond Air is performing preclinical testing of the use of ultra-high concentrations of NO with a proprietary delivery system, separate from LungFit™, to target certain solid tumors.